For Black and Indigenous individuals and People of Color with IBD, disparities are experienced throughout the continuum of care from prevention to diagnosis and treatment. And as an inclusive, patient-centered biopharmaceutical company, we at Bristol Myers Squibb (BMS) are committed to helping to advance health equity: the assurance that everyone has a fair and just opportunity to achieve optimal health outcomes. We are united by a critical mission: transforming patients’ lives through science by discovering, developing, and delivering innovative medicines that help them prevail over serious diseases.
Through our bold Diversity and Inclusion and Health Equity commitments made in August 2020, we are investing $150 million across five focus areas, one of which is addressing health disparities. As part of these efforts, we are raising disease awareness and education for medically underserved communities.
We are also engaging in listening sessions and conversations with patient advocacy groups, medical societies, and industry peers – like our participation in COCCI’s Equity in IBD Patient Symposium – to more deeply understand challenges in patients’ journeys and collaboratively develop sustainable solutions. And we are also ensuring that patients are at BMS tables providing guidance on clinical trials and development programs through our Patient Expert Engagement Resource (PEER) program.
Centering health equity in our work for and with patients is critical and an opportunity to expand our science, further deliver on our mission, and, most importantly, improve the health outcomes of patients and communities.
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.
This is a sponsored post by Bristol Myers Squibb